Liposome‐encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first‐line therapy of metastatic breast carcinoma

2001509 citationsJournal Articlebronze Open Access

Authors

Single-agent TLC D-99 produces less cardiotoxicity than doxorubicin, while providing comparable antitumor activity.

Good health and well-being

Published in: Cancer

Volume 94, Issue 1, pp. 25-36

Field-Weighted Citation Impact: 5.91